Adocia announced that it was notified in a letter dated January 26 from Eli Lilly and Company its decision to terminate the December 2014 Collaboration Research and License Agreement for the development of Adocia's ultra-rapid insulin, known as BioChaperone Lispro, for treatment in people with type 1 and type 2 diabetes. As a consequence of such decision and according to the terms of this agreement, the rights that Adocia has licensed to Lilly will revert to Adocia at no cost.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.67 EUR | +8.00% |
|
-21.58% | -50.87% |
07-11 | ADOCIA : price target reduced by Oddo BHF | CF |
07-10 | Adocia, Tonghua Dongbao End Insulin Combo License Deal | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-50.87% | 92.81M | |
+20.17% | 126B | |
+24.67% | 118B | |
+25.44% | 27.87B | |
-17.74% | 20.95B | |
-15.17% | 16.92B | |
-15.21% | 16.18B | |
+11.91% | 14.84B | |
-47.10% | 14.79B | |
+54.50% | 14.08B |
- Stock Market
- Equities
- ADOC Stock
- News Adocia
- Adocia Announces the Termination by Eli Lilly and Company of the Collaboration on BioChaperone Lispro